Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02362646 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
A Phase 2 study, sponsored by Annetine Gelijns.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT02362646 is a Phase 2 study that has completed, run by Annetine Gelijns. The registered enrollment target is 159 participants.
The verdict
NCT02362646, a Phase 2 study, has completed, sponsored by Annetine Gelijns.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.
Interventions
- BIOLOGICAL MPC Intramyocardial Injection
- DRUG Control Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02362646
The ClinicalTrials.gov registry entry for NCT02362646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annetine Gelijns, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MPC Intramyocardial Injection is the first listed.
NCT02362646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02362646 about?
NCT02362646 is a clinical study titled "Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients". The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow and have been shown to increase the development of blood vess...
What is the current status of trial NCT02362646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2015-07. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT02362646?
The interventions under investigation include: MPC Intramyocardial Injection (BIOLOGICAL), Control Solution (DRUG).
Who is sponsoring clinical trial NCT02362646?
This trial is sponsored by Annetine Gelijns, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.